Focus: Tenaya Therapeutics is a public-stage cardiovascular biotech focused on rare genetic cardiomyopathies and metabolic diseases. The company operates with a lean preclinical/early-stage pipeline centered on gene therapy and novel molecular approaches.
Profile data last refreshed 14h ago · AI intelligence enriched 1mo ago
No open roles listed right now. Follow Tenaya Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Tenaya Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tenaya Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy - GlobeNewswire
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy GlobeNewswire
A heart-disease biotech will meet investors at two September conferences - Stock Titan
A heart-disease biotech will meet investors at two September conferences Stock Titan
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewswire
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences GlobeNewswire
Israel Englander group takes passive stake in Tenaya Therapeutics (TNYA) - Stock Titan
Israel Englander group takes passive stake in Tenaya Therapeutics (TNYA) Stock Titan
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301 - Yahoo Finance
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301 Yahoo Finance
Tenaya Therapeutics, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Tenaya Therapeutics, Inc. SEC Filing (Aug 17, 2026) Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo